Pancytopenia, fever, rash, and hepatomegaly should raise suspicion of enteric fever, leptospirosis and erythema infectiosum. Parvovirus B19 is a DNA virus of the Parvoviridae family. Human Parvovirus B19 (B19V) infection usually causes erythema infectiosum (fifth disease). The “slapped cheek” appearance and lacey erythema of the proximal extremities is the most common clinical manifestation of parvovirus B19 infection, occurring most frequently in school-aged children.
1 In recent decades, several uncommon exanthems have been described in association with B19V.
2 Parvovirus B19 infection may be indistinguishable from other viral illnesses in the absence of the classic exanthema. Children are often febrile, but their appearance is non-toxic and the prodrome is nonspecific.
3 Apart from measles, rubella, exanthem subitum, scarlet fever, and infectious erythema, systemic rashes are also found in other bacterial infections, including leptospirosis, mycoplasma infection, and disseminated gonococcal infection. In addition, systemic rashes are found in tinea versicolor, enteroviral infections, Gianotti-Crosti syndrome and papular-purpuric gloves and socks syndrome.
4 Infection due to parvovirus B19 is self-limiting and has an excellent prognosis. However, in high-risk pediatric groups (e.g. immunocompromised patients, children with hemolytic anemia or prenatal infection), clinical manifestations are of pure red-cell aplasia (PRCA) resulting in chronic or recurrent anemia with reticulocytopenia. Bone-marrow involvement can also manifest as neutropenia, agranulocytosis, pancytopenia, thrombocytopenia, and hemophagocytosis.
5 Treatment is aimed at symptomatic relief, and a vaccine currently is under investigation.
6 Red-cell transfusions may be required till the immune system can reconstitute. If immune reconstitution is not expected or will be delayed, passive administration of B19 antibodies will lead to virus neutralization, resumption of reticulocytosis, and a rise in hematocrit. However, relapses may occur as the passive antibody wanes if the host has not yet been able to produce neutralizing antibody. In the majority of reported cases, only one course of
IVIG has been needed for long-term remission.
5 B19V still lacks a specific antiviral therapy although the antiviral activity of
Cidofovir is shown to be effective.
7References : |
- Chinsky JM, Kalyani RR. Fever and petechial rash associated with parvovirus B19 infection. Clin Pediatr (Phila). 2006;45:275-80.
- Tuccio A, Zanelli G, Rodriguez DC, Tataranno ML, Vascotto M, Balestri P. Petechial rash associated with Parvovirus B19 in children: case report and literature review. Infez Med. 2014;22:250-4.
- Cennimo DJ, Dieudonne A. Parvovirus B19 infection. Available at http://emedicine.medscape.com. Retrieved on 25th December 2018
- Kang JH. Febrile illness with skin rashes. Infection & chemotherapy. 2015;47:155-66.
- Landry ML. Parvovirus B19. Microbiol Spectr. 2016;4. doi: 10.1128/microbiolspec.DMIH2-0008-2015.
- Valentin MN, Cohen PJ. Pediatric parvovirus B19: spectrum of clinical manifestations. Cutis. 2013;92:179-84
- Bonvicini F, Bua G, Manaresi E, Gallinella G. Antiviral effect of cidofovir on parvovirus B19 replication. Antiviral Res. 2015;113:11-8.
|